Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype
暂无分享,去创建一个
J. Pettitt | A. V. van Wijnen | T. L. Andersen | H. Driscoll | A. Dudakovic | M. Kassem | C. Rosen | M. McDonald | M. Reagan | M. Hinge | V. Demambro | Connor S. Murphy | C. Falank | M. Farrell | A. Jafari | H. Fairfield | C. Lary | S. Costa | Casper M Khatib | Victoria E Demambro | C. M. Khatib
[1] F. Prósper,et al. Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment , 2020, Haematologica.
[2] Beatriz Gámez,et al. Myeloma Cells Down‐Regulate Adiponectin in Bone Marrow Adipocytes Via TNF‐Alpha , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] G. Colditz,et al. Elucidating Under-Studied Aspects of the Link Between Obesity and Multiple Myeloma: Weight Pattern, Body Shape Trajectory, and Body Fat Distribution , 2019, JNCI cancer spectrum.
[4] P. L. Bergsagel,et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease , 2019, Science Translational Medicine.
[5] Matthew S Macauley,et al. Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model , 2019, Haematologica.
[6] L. Liaw,et al. Development of a 3D bone marrow adipose tissue model. , 2018, Bone.
[7] Joshua M. Korn,et al. Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.
[8] Liming Huang,et al. Tumor-Infiltrating Podoplanin+ Fibroblasts Predict Worse Outcome in Solid Tumors , 2018, Cellular Physiology and Biochemistry.
[9] H. Unverdi,et al. Stromal podoplanin expression and its clinicopathological role in breast carcinoma. , 2018, The Malaysian journal of pathology.
[10] H. Hua,et al. PARP9 is overexpressed in human breast cancer and promotes cancer cell migration. , 2018, Oncology letters.
[11] Jinhua Zhang,et al. S100A4 protects mice from high-fat diet-induced obesity and inflammation , 2018, Laboratory Investigation.
[12] J. Pettitt,et al. The skeletal cell‐derived molecule sclerostin drives bone marrow adipogenesis , 2018, Journal of cellular physiology.
[13] M. Reagan,et al. Myeloma-Associated Adipocytes Exhibit Reduced Adipogenic Gene Expression and Delipidation , 2017 .
[14] M. Reagan,et al. New Bone Cell Type Identified as Driver of Drug Resistance in Multiple Myeloma: The Bone Marrow Adipocyte , 2017 .
[15] N. LeBrasseur,et al. Targeting cellular senescence prevents age-related bone loss in mice , 2017, Nature Medicine.
[16] D. Hose,et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. , 2017, Blood.
[17] M. Evans,et al. Techniques to Induce and Quantify Cellular Senescence. , 2017, Journal of visualized experiments : JoVE.
[18] R. Baron,et al. Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. , 2017, Cell metabolism.
[19] E. K. Parkinson,et al. Fibroblast activation and senescence in oral cancer , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[20] Benjamin G. Bitler,et al. HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci , 2016, The Journal of cell biology.
[21] T. Trotter,et al. Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. , 2016, The American journal of pathology.
[22] U. Andersson,et al. TLR4-dependant pro-inflammatory effects of HMGB1 on human adipocyte , 2016, Adipocyte.
[23] S. Davison,et al. Adipocytes contribute to the growth and progression of multiple myeloma: Unraveling obesity related differences in adipocyte signaling. , 2016, Cancer letters.
[24] J. Delaissé,et al. Early reversal cells in adult human bone remodeling: osteoblastic nature, catabolic functions and interactions with osteoclasts , 2016, Histochemistry and Cell Biology.
[25] U. Galderisi,et al. Myeloma cells can corrupt senescent mesenchymal stromal cells and impair their anti-tumor activity , 2015, Oncotarget.
[26] R. Orlowski,et al. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation , 2015, Oncotarget.
[27] L. Liaw,et al. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. , 2015, Bone.
[28] N. LeBrasseur,et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs , 2015, Aging cell.
[29] C. Castoro,et al. Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion , 2015, Oncotarget.
[30] D. Kaplan,et al. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. , 2014, Blood.
[31] Asha A. Nair,et al. High‐Resolution Molecular Validation of Self‐Renewal and Spontaneous Differentiation in Clinical‐Grade Adipose‐Tissue Derived Human Mesenchymal Stem Cells , 2014, Journal of cellular biochemistry.
[32] Degui Zhi,et al. The Bioenergetic Health Index: a new concept in mitochondrial translational research , 2014, Clinical science.
[33] E. Haralambieva,et al. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN&ggr;–STAT1–IRF1–p53 axis in diffuse large B-cell lymphoma , 2013, Journal of Cell Science.
[34] L. Lagneaux,et al. Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells , 2013, PloS one.
[35] Bolin Liu,et al. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. , 2013, American journal of translational research.
[36] A. Aponte,et al. Platelet Mitochondrial Dysfunction is Evident in Type 2 Diabetes in Association with Modifications of Mitochondrial Anti-Oxidant Stress Proteins , 2011, Experimental and Clinical Endocrinology & Diabetes (Barth).
[37] R. Kyle,et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. , 2011, Blood.
[38] J. Gil,et al. A role for CXCR2 in senescence, but what about in cancer? , 2009, Cancer research.
[39] Judith Campisi,et al. Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.
[40] F. Davies,et al. Proteomic evaluation of pathways associated with dexamethasone‐mediated apoptosis and resistance in multiple myeloma , 2007, British journal of haematology.
[41] Rafael Fonseca,et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.
[42] K. Vanderkerken,et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells , 2007, Leukemia.
[43] K. Kristiansen,et al. Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. , 2006, Molecular endocrinology.
[44] A. Strosberg,et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes , 2001, Molecular and Cellular Endocrinology.
[45] R. Aguiar,et al. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. , 2000, Blood.
[46] K. Anderson,et al. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. , 1997, Blood.
[47] D. DeFranco,et al. Selectivity of Cell Cycle Regulation of Glucocorticoid Receptor Function (*) , 1995, The Journal of Biological Chemistry.